



The OncoSim-Breast model: reproducing the observed effects of breast cancer screening in a randomized clinical trial

Jean H.E. Yong, Bill Flanagan, Claude Nadeau, Natalie Fitzgerald, Saima Memon, Tallal Younis, Nicole Mittmann, Andrew Coldman, Michael Wolfson, Anthony Miller

Canadian Partnership Against Cancer, Statistics Canada, Dalhousie University, University of Toronto, University of British Columbia, University of Ottawa

ONCOSIM-BREAST VS TRIAL DATA

Annual breast cancer screening in women aged 40-49 vs. no screening



OncoSim's projections were within the trial's observed confidence intervals.

SO WHAT? OncoSim's ability to reproduce observed data increases our confidence when using its model results to inform breast cancer screening-related policy decisions.

- OncoSim-Breast simulates the natural history of breast cancer.
- It was built using Canadian data to evaluate cancer control strategies.
- We replicated the Age trial in OncoSim-Breast and compared the projected outcomes with the observed data.

- The UK Age trial is a randomized trial of annual breast cancer screening in women aged 40-49 years.
- Other established breast cancer models have validated their projections against the Age trial.²

About OncoSim

OncoSim is a free, web-based cancer simulation tool combining data from the real world, expert opinion, and the published literature. Its projections have been used by decision makers across Canada to support cancer control decisions. OncoSim is led and supported by the Canadian Partnership Against Cancer, with model development by Statistics Canada, and is made possible through funding by Health Canada.

References

1. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. *The lancet oncology* 2015; 16(9): 1123-32.
2. van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, et al. Comparing CISNET breast cancer incidence and mortality predictions to observed clinical trial results of mammography screening from ages 40 to 49. *Medical Decision Making* 2018; 38(1_suppl): 140S-50S.